RSA Recognized in 2024 Gartner® Magic Quadrant™ for Access Management
RSA, the security-first identity leader, announced today that RSA® ID Plus, the world’s most secure identity and access management (IAM) platform has been named a Niche Player in the 2024 Gartner® Magic Quadrant™ for Access Management.
With only ten organizations named to the Gartner report, RSA believes that the Magic Quadrant signals the world’s top IAM vendors. ID Plus brings comprehensive identity protection to some of the world’s most security-sensitive organizations across banking, securities, insurance, and government. Available as SaaS, on-premises, or in hybrid configurations, ID Plus offers organizations flexibility in deployment and specialization in high-security workforce environments. Through various subscription models featuring a range of editions and add-ons, ID Plus meets diverse needs, supporting the evolving workforce requirements and regulatory landscapes throughout North America, South America, Europe, and the Asia-Pacific markets.
RSA believes that several capabilities and strengths contributed to ID Plus being listed in the 2024 Gartner Magic Quadrant for Access Management, including:
- High customer satisfaction and retention
- Specialization in workforce use cases, particularly for high-security verticals
- Broad support for cloud, hybrid, and on-premises environments
- A high-availability, high-security failover process that ensures uninterrupted access even during cloud outages
- Integrations with existing data and applications that enable buyers to maintain local configurations
“For decades, RSA has set the standard in secure authentication, but our story goes far beyond that. Seeing ID Plus break into the 2024 Gartner Magic Quadrant for Access Management and being recognized as a workforce security specialist, we feel, highlights the work we’ve done to develop a unified identity platform capable of securing the entire identity lifecycle and protecting highly regulated industries,” said RSA CEO Rohit Ghai.
“We feel that being named to the Gartner Magic Quadrant establishes RSA as one of the world’s top ten IAM vendors, and we’re not planning on going anywhere,” said RSA Chief Product and Technology Officer Jim Taylor, who detailed why workforce access management challenges organizations, how RSA supports customer access management, and the organization's access management roadmap in a new blog post. “Workforce access management is hard because it demands balancing security, usability, and scalability without getting any component wrong. I’d rather RSA be known as a workforce security specialist than an access generalist: that’s always been where RSA delivers the most value and what our customers need. With hundreds of IAM vendors worldwide, this recognition validates our commitment to delivering the full range of access, authentication, governance, and lifecycle capabilities that every organization requires.”
“While we may be new to the Magic Quadrant, security-first industries have relied on our access management solutions for years,” said RSA President and Chief Business Officer Greg Nelson. “Security-first leaders in government, finance, energy, and other regulated industries have long trusted RSA to deliver robust identity security solutions. We believe this recognition from Gartner underscores the strength of our strategy and reinforces our commitment to lead across every component of identity.”
Recent enhancements to ID Plus—including expanded identity insights, Bring Your Own Identity (BYOI) options, and OAuth 2.0 capabilities supporting machine-to-machine and IoT access—will bring further workforce security depth to the solution. RSA will introduce mobile passkey functionality, advanced directory enhancements, and increased AI and machine learning capabilities to assist security administrators in mitigating evolving threats.
RSA will showcase these innovations at the Gartner Identity & Access Management Summit from December 9-11 in Grapevine, Texas. Attendees are invited to visit RSA at booth 633 to experience demonstrations of the latest passwordless authentication and identity governance and administration (IGA) advancements. Book your demo with RSA at the Gartner IAM Summit now.
Resources
Read Jim Taylor’s blog post
Book your demo with RSA at the Gartner Identity & Access Management Summit
Start your free, 45-day trial of RSA ID Plus today
About RSA
The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205057055/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom